Glycemic treatment

被引：6

作者：

Bloomgarden, ZT ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Ctr Diabet, New York, NY 10029 USA

来源：

DIABETES CARE | 2004年 / 27卷 / 05期

关键词：

D O I：

10.2337/diacare.27.5.1227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1227 / 1234

页数：8

共 40 条

[1] Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice [J].

Alberts, P ;

Engblom, L ;

Edling, N ;

Forsgren, M ;

Klingström, G ;

Larsson, C ;

Rönquist-Nii, Y ;

Öhman, B ;

Abrahmsén, L .

DIABETOLOGIA, 2002, 45 (11) :1528-1532

[2]

*AM PHARM, EX SYNTH EX 4

[3]

Borch-Johnsen K, 1999, LANCET, V354, P617

[4] Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].

Buchanan, TA ;

Xiang, AH ;

Peters, RK ;

Kjos, SL ;

Marroquin, A ;

Goico, J ;

Ochoa, C ;

Tan, S ;

Berkowitz, K ;

Hodis, HN ;

Azen, SP .

DIABETES, 2002, 51 (09) :2796-2803

[5] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].

Chiasson, JL ;

Josse, RG ;

Gomis, R ;

Hanefeld, M ;

Karasik, A ;

Laakso, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494

[6] The lipid phosphatase SHIP2 controls insulin sensitivity [J].

Clément, S ;

Krause, U ;

Desmedt, F ;

Tanti, JF ;

Behrends, J ;

Pesesse, X ;

Sasaki, T ;

Penninger, J ;

Doherty, M ;

Malaisse, W ;

Dumont, JE ;

Le Marchand-Brustel, Y ;

Erneux, C ;

Hue, L ;

Schurmans, S .

NATURE, 2001, 409 (6816) :92-97

[7] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[8] DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].

DEACON, CF ;

JOHNSEN, AH ;

HOLST, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957

[9] Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency [J].

Draper, N ;

Walker, EA ;

Bujalska, IJ ;

Tomlinson, JW ;

Chalder, SM ;

Arlt, W ;

Lavery, GG ;

Bedendo, O ;

Ray, DW ;

Laing, I ;

Malunowicz, E ;

White, PC ;

Hewison, M ;

Mason, PJ ;

Connell, JM ;

Shackleton, CHL ;

Stewart, PM .

NATURE GENETICS, 2003, 34 (04) :434-439

[10] Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene [J].

Elchebly, M ;

Payette, P ;

Michaliszyn, E ;

Cromlish, W ;

Collins, S ;

Loy, AL ;

Normandin, D ;

Cheng, A ;

Himms-Hagen, J ;

Chan, CC ;

Ramachandran, C ;

Gresser, MJ ;

Tremblay, ML ;

Kennedy, BP .

SCIENCE, 1999, 283 (5407) :1544-1548

← 1 2 3 4 →